Market Cap | 109.38M | P/E | - | EPS this Y | -1,284.30% | Ern Qtrly Grth | - |
Income | -33.09M | Forward P/E | -6.23 | EPS next Y | 30.00% | 50D Avg Chg | 2.00% |
Sales | 22.34M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 43.00% |
Dividend | N/A | Price/Book | 5.23 | EPS next 5Y | - | 52W High Chg | -32.00% |
Recommedations | 3.00 | Quick Ratio | 5.03 | Shares Outstanding | 5.27M | 52W Low Chg | 183.00% |
Insider Own | 7.64% | ROA | -35.51% | Shares Float | 4.38M | Beta | 0.83 |
Inst Own | 42.00% | ROE | -105.87% | Shares Shorted/Prior | 40.87K/27.81K | Price | 20.76 |
Gross Margin | -31.85% | Profit Margin | -148.13% | Avg. Volume | 73,398 | Target Price | 21.00 |
Oper. Margin | -141.05% | Earnings Date | Aug 3 | Volume | 36,083 | Change | -0.76% |
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Oppenheimer | Outperform | Dec 9, 21 |
Cantor Fitzgerald | Overweight | Sep 28, 18 |
Cantor Fitzgerald | Overweight | Jun 12, 18 |
Mizuho | Neutral | Nov 30, 12 |
B. Riley FBR | Neutral | May 5, 18 |
Evercore Partners | Equal-Weight | Oct 31, 12 |
Wedbush | Neutral | Aug 8, 12 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Ellison Mark Jason Heath | Chief Development Of.. Chief Development Officer | Jan 09 | Sell | 20.20 | 469 | 9,474 | 19,361 | 01/09/23 |
Skolnick Phil | Chief Scientific Off.. Chief Scientific Officer | Jan 09 | Sell | 20.20 | 369 | 7,454 | 22,028 | 01/09/23 |
CRYSTAL ROGER | Chief Executive Offi.. Chief Executive Officer | Jan 09 | Sell | 20.20 | 1,183 | 23,897 | 76,697 | 01/09/23 |
O'Toole David D | Chief Financial Offi.. Chief Financial Officer | Jan 05 | Sell | 20.20 | 1,600 | 32,320 | 35,204 | 01/05/23 |
O'Toole David D | Chief Financial Offi.. Chief Financial Officer | Jul 14 | Sell | 11.10 | 779 | 8,647 | 36,804 | 07/15/22 |
Skolnick Phil | Chief Scientific Off.. Chief Scientific Officer | Jul 14 | Sell | 11.85 | 627 | 7,430 | 23,818 | 07/15/22 |
Sinclair Michael | Director Director | Jun 02 | Sell | 13.74 | 20,000 | 274,800 | 49,220 | 06/06/22 |
Collard Craig A | Director Director | May 13 | Buy | 10.49 | 3,689 | 38,698 | 20,972 | 05/16/22 |
MacDougall Ann L. | Director Director | May 13 | Buy | 10.926 | 3,000 | 32,778 | 26,179 | 05/16/22 |
Skolnick Phil | Chief Scientific Off.. Chief Scientific Officer | Jan 27 | Sell | 26.19 | 1,518 | 39,756 | 22,445 | 01/27/22 |
CRYSTAL ROGER | Chief Executive Offi.. Chief Executive Officer | Jan 27 | Sell | 26.15 | 1,995 | 52,169 | 78,488 | 01/27/22 |
O'Toole David D | Chief Financial Offi.. Chief Financial Officer | Jan 10 | Sell | 30.60 | 432 | 13,219 | 35,583 | 01/12/22 |
Skolnick Phil | Chief Scientific Off.. Chief Scientific Officer | Jan 10 | Sell | 30.49 | 385 | 11,739 | 23,963 | 01/12/22 |
CRYSTAL ROGER | Chief Executive Offi.. Chief Executive Officer | Jan 10 | Sell | 30.49 | 1,058 | 32,258 | 80,483 | 01/12/22 |